Detailed information for compound 314152

Basic information

Technical information
  • TDR Targets ID: 314152
  • Name: 2-[[4-(4-fluoro-3-methylphenyl)-3-phenoxybenz oyl]amino]benzoic acid
  • MW: 441.45 | Formula: C27H20FNO4
  • H donors: 2 H acceptors: 3 LogP: 6.45 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(c1ccc(c(c1)Oc1ccccc1)c1ccc(c(c1)C)F)Nc1ccccc1C(=O)O
  • InChi: 1S/C27H20FNO4/c1-17-15-18(12-14-23(17)28)21-13-11-19(16-25(21)33-20-7-3-2-4-8-20)26(30)29-24-10-6-5-9-22(24)27(31)32/h2-16H,1H3,(H,29,30)(H,31,32)
  • InChiKey: YCNJYPVQZBJJOO-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[[4-(4-fluoro-3-methyl-phenyl)-3-phenoxy-benzoyl]amino]benzoic acid
  • 2-[[[4-(4-fluoro-3-methylphenyl)-3-phenoxyphenyl]-oxomethyl]amino]benzoic acid
  • 2-[[4-(4-fluoro-3-methyl-phenyl)-3-phenoxy-phenyl]carbonylamino]benzoic acid
  • 2-[[4-(4-fluoro-3-methylphenyl)-3-(phenoxy)benzoyl]amino]benzoic acid
  • 2-[[4-(4-fluoro-3-methyl-phenyl)-3-(phenoxy)benzoyl]amino]benzoic acid
  • 2-[[[4-(4-fluoro-3-methylphenyl)-3-(phenoxy)phenyl]-oxomethyl]amino]benzoic acid
  • 2-[[4-(4-fluoro-3-methyl-phenyl)-3-(phenoxy)phenyl]carbonylamino]benzoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Enterococcus faecalis (strain ATCC 700802 / V583) Beta-ketoacyl-ACP synthase III Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Plasmodium knowlesi beta-ketoacyl-acyl carrier protein synthase III precursor, putative Get druggable targets OG5_129509 All targets in OG5_129509
Chlamydia trachomatis oxoacyl-ACP synthase III Get druggable targets OG5_129509 All targets in OG5_129509
Neospora caninum 3-oxoacyl-(acyl-carrier-protein) synthase III family protein, putative Get druggable targets OG5_129509 All targets in OG5_129509
Mycobacterium tuberculosis 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) Get druggable targets OG5_129509 All targets in OG5_129509
Wolbachia endosymbiont of Brugia malayi 3-oxoacyl-ACP synthase Get druggable targets OG5_129509 All targets in OG5_129509
Mycobacterium ulcerans 3-oxoacyl-ACP synthase Get druggable targets OG5_129509 All targets in OG5_129509
Plasmodium berghei apicoplast beta-ketoacyl-acyl carrier protein synthase III precursor, putative Get druggable targets OG5_129509 All targets in OG5_129509
Mycobacterium ulcerans 3-oxoacyl-ACP synthase Get druggable targets OG5_129509 All targets in OG5_129509
Plasmodium falciparum beta-ketoacyl-ACP synthase III Get druggable targets OG5_129509 All targets in OG5_129509
Plasmodium vivax beta-ketoacyl-acyl carrier protein synthase III precursor, putative Get druggable targets OG5_129509 All targets in OG5_129509
Mycobacterium ulcerans beta-ketoacyl synthase-like protein Get druggable targets OG5_129509 All targets in OG5_129509
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Mycobacterium tuberculosis Conserved hypothetical protein Beta-ketoacyl-ACP synthase III   321 aa 310 aa 21.9 %
Schistosoma japonicum ko:K01641 hydroxymethylglutaryl-CoA synthase [EC2.3.3.10], putative Beta-ketoacyl-ACP synthase III   321 aa 271 aa 22.1 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Wolbachia endosymbiont of Brugia malayi 3-oxoacyl-ACP synthase 0.0383 0.5 0.5
Mycobacterium ulcerans 3-oxoacyl-ACP synthase 0.0383 0.5 0.5
Mycobacterium tuberculosis 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) 0.0383 0.5 0.5
Mycobacterium ulcerans beta-ketoacyl synthase-like protein 0.0383 0.5 0.5
Plasmodium falciparum beta-ketoacyl-ACP synthase III 0.0383 0.5 0.5
Mycobacterium ulcerans 3-oxoacyl-ACP synthase 0.0383 0.5 0.5
Plasmodium vivax beta-ketoacyl-acyl carrier protein synthase III precursor, putative 0.0383 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
-logMIC (functional) = 6.155 Antibacterial activity against Escherichia coli ChEMBL. 17707951
IC50 (binding) = 6.619 Inhibition of Enterococcus faecalis FabH by FabD/FabH coupled assay ChEMBL. 17707951
IC50 (binding) = 0.24 uM Inhibitory concentration against Enterococcus faecalis beta-Ketoacyl-acyl carrier protein synthase III ChEMBL. 15743201
IC50 (binding) = 0.24 uM Inhibitory concentration against Enterococcus faecalis beta-Ketoacyl-acyl carrier protein synthase III ChEMBL. 15743201
MIC (functional) = 0.7 ug ml-1 Minimum inhibitory concentration against Streptococcus pneumonia ATCC 6301 ChEMBL. 15743201
MIC (functional) = 0.7 ug ml-1 Minimum inhibitory concentration against Neisseria meningitides MC58 in presence of membrane permeablizing agent polymyxin B ChEMBL. 15743201
MIC (functional) = 0.7 ug ml-1 Minimum inhibitory concentration against Escherichia coli TolC- mutant in presence of membrane permeablizing agentpolymyxin B ChEMBL. 15743201
MIC (functional) = 0.7 ug ml-1 Minimum inhibitory concentration against Escherichia coli TolC- mutant in presence of membrane permeablizing agentpolymyxin B ChEMBL. 15743201
MIC (functional) = 2.8 ug ml-1 Minimum inhibitory concentration against Streptococcus pyogenes NZ131 ChEMBL. 15743201
MIC (functional) = 2.8 ug ml-1 Minimum inhibitory concentration against Enterococcus faecalis VRE 583 ChEMBL. 15743201
MIC (functional) = 5.6 ug ml-1 Minimum inhibitory concentration against Staphylococcus aureus MRSA 703 ChEMBL. 15743201

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.